Alzecure Pharma Ab · OMXSTO:ALZCUR
Alzecure Pharma Ab — Investor Presentation (May 2021)
10 slides from Alzecure Pharma Ab's investor presentation, May 11, 2021
Slide 1: Company Overview & Goals
Martin Jönsson CEO May 11, 2021 Company Overview & Goals
Slide 2: AlzeCure Pharma
AlzeCure Pharma Founded in 2016, out of a research foundation sponsored by Alzheimerfonden Experienced team with extensive background within Pharma industry Based at Novum Science Park, Karolinska Institute, Stockholm, Sweden Working in Alzheimer’s Disease (AD) and Pain – multi-billion marke
Slide 3: Our Business Model
Our Business Model • We are a Research & Development company • Research & develop to early clinical phase and then out-license our projects • Gain incomes through: − Upfront payments, − Milestone payments and − Royalties on sold products 3
Slide 4: Alzheimer's Disease
Our primary Focus area Alzheimer’s Disease • Costs the society more than oncology and cardiovascular diseases TOGETHER • The patient population and costs will TRIPLE in the next 30 years 4
Slide 5: Two Alzheimer's platforms - 1st-in-class properties & potential game-changers
Two Alzheimer’s platforms - 1st-in-class properties & potential game- changers TARGET TWO KEY AREAS WITH A HIGH UNMET MEDICAL NEED Disease-modifying therapy Symptomatic therapy Alzstatin® NeuroRestore ® Targeting Amyloid Production Improving Neuronal Function - Novel Oral Small Molecule - Novel Oral
Slide 6: Pain
Our second Focus area Pain • Suicide due to chronic pain is as common as due to depression • Most common cause for sick leaves, creating high societal costs • Opioid crisis in the US is huge – reversing the mean average lifespan of Americans Huge need for more efficacious and safer treatments 6
Slide 7: Our platform PAINLESS – Targeting unmet medical needs within pain
Our platform PAINLESS – Targeting unmet medical needs within pain Neuropathic pain* Osteoarthritis & severe pain conditions 25 – 30 million patients 250 – 300 million patients Project: ACD440 Project: TrkA-NAM 7 *) Neuropathic pain = Pain initiated or caused by a primary lesion or dysfunction in the
Slide 8: NeuroRestore: A pipeline of small-molecule programs
A pipeline of small-molecule programs – Multiple candidates increase chance of success Platform Candidate Indication Research phase Preclinical phase Phase I Phase II Phase III Alzheimer’s Disease, NeuroRestore® Sleep disorders, Ongoing ACD856 Traumatic brain injuries Parkinson’s disease Fully funde
Slide 9: Key short-term milestones for 2021
Key short-term milestones for 2021 Read-out of clinical 1b study Painless ACD440 in summer 2021 Read-out of clinical 1a SAD study NeuroRestore® ACD856 summer 2021 Start NeuroRestore® ACD856 1a MAD clinical study in second half 2021 Select CD for our pain project TrkA-NAM in second half 2021 m File f
Slide 10: Karolinska Institutet Novum Science Park contact details
Karolinska Institutet Novum Science Park Hälsovägen 7, 141 57 Huddinge, Stockholm www.alzecurepharma.se